BioPharma Today

Pharma's New Marketing Realities

Article preview from IN VIVO January 27, 2009

With the traditional pharmaceutical commercial model in disarray, companies are looking for new approaches to maintaining their competitive position. Read on...

A Goliath Grows: Pfizer Buys Wyeth For $68 Billion

Article preview from"The Pink Sheet" DAILY January 27, 2009

In the largest pharma merger in history, Pfizer will acquire rival Wyeth in a deal valued at approximately $68 billion, a combination that could usher in a new era of consolidation within the drug industry. Read more now...

The Asia Corner - From the Editors of PharmAsia News

The Asia Corner - From the Editors of PharmAsia News January 27, 2009

In this BioPharma Today feature, the editors of PharmAsia News take a closer look each week at the most important biopharma developments from China, India, Japan and the Pacific Rim.

Read today's features...

CMS Administrator: The Pick Has Been Made, But Who Is It?

Full article preview from The RPM Report January 27, 2009

The Obama Administration is understood to have made its choice for the next head of the Medicare agency. Will it be an MD? Find out now...
 

Smaller DTC Budgets, But More Info-Packed Drug Ads Expected In 2009

Full article reprinted from "The Pink Sheet" January 27, 2009

Drug companies will continue to scale back funds for televised ads in 2009, largely in order to save money, but also because they are increasingly sensitive to public perception at a time when consumers are struggling financially.  Read more here...

Gates Calls For “Innovation” To End Polio

The Gates Foundation, Rotary International and the governments of the United Kingdom and Germany pledged a combined $640 million last week to help eradicate polio, an effort that has cost the global health community more than $6 billion since 1988.

Ending the Arms Race: Ten Priorities for Fixing the Commercial Model

Article preview from IN VIVO January 20, 2009

Faced with growing budgets and declining effectiveness of commercial spending, most large companies have embarked on the next wave of significant commercial changes. But most of these efforts don't go far enough to address the rapid and fundamental changes in the stakeholder landscape which have knocked pharma dramatically out of alignment with its stakeholder base. Read more now...

The Asia Corner - From the Editors of PharmAsia News

January 20, 2009

In this BioPharma Today feature, the editors of PharmAsia News take a closer look each week at the most important biopharma developments from China, India, Japan and the Pacific Rim.

Read today's features...

Venture Prepares for Structured Acquisitions

Full article reprinted from Start-Up January 20, 2009

With Big Pharma content to sit on the sidelines and wait as biotech company valuations continue their fall, the M&A activity that does take place is likely to place a premium on hedging risk. And, say venture investors, that means structured acquisitions of biotech firms are likely to increase as pharmaceutical acquirers gain more leverage over cash-strapped firms in deal negotiations. Read on now...

Race For White Oak Almost Over: Will It End With Sharfstein Or Califf At FDA?

Article preview from "The Pink Sheet" January 20, 2009

Find out why The Senate confirmation of a permanent FDA commissioner could come as early as March now that the Obama transition team has apparently concluded its search for Andrew von Eschenbach's successor...